Introduction
Chronic heart failure (CHF) is a common final stage of many heart diseases and represents a major cause of death and disability worldwide, 1 and is a health issue associated with increasing healthcare expenditures. 2 The prevalence of CHF is constantly rising: the lifetime risk of developing CHF is one in five and an estimated number of 26 million patients worldwide suffer from it. 3 -5 Therefore, the identification of important risk factors for adverse clinical events in the heart failure (HF) population is a crucial first step in the development of strategies that may improve outcomes. The association between low blood pressure (BP) and prognosis in the general population remains controversial; 6 current evidence comes mostly from BP-lowering trials in the hypertensive population. 6 However, CHF patients have different co-morbidities, different treatment goals and a poorer prognosis compared with hypertensive individuals. While the treatment goal in hypertensive patients is to lower BP to improve prognosis, the focus of CHF management is to improve prognosis by prescribing different types of drugs that have demonstrated improved mortality rates, although some incidentally even have an antihypertensive effect.
Intriguingly, standard HF therapy (consisting of, among others, loop diuretics, inhibitors of the renin-angiotensin-aldosterone system and beta-blockers) induces hypotension, and current HF guidelines recommend uptitrating medications to the tolerance of patients, which may be lower than doses studied in clinical trials. 4 Until recently, the variability of office BP was dismissed as random fluctuation around a patient's so-called 'true blood pressure'. 7, 8 While in hypertensive patients a higher visit-to-visit variability of systolic BP (SBP) has been associated with an increased risk of cardiovascular disease and mortality, 9 data in HF patients are sparse and come from retrospective analyses of randomized clinical trials.
10 Therefore, the aim of the present study was to further delineate the influence of long-term BP changes on prognosis in a real-world cohort of CHF patients.
Methods

Participants
In this retrospective, longitudinal study, patients with stable CHF based on current or past clinical symptoms, signs and echocardiographic findings according to current guidelines 4 were analysed at the University Hospital Zurich between August 1998 and July 2011. The collected data of all patients included were analysed from the moment of first visit at the outpatient department of our HF clinic, no matter at what time patients were diagnosed with HF. The only exclusion criterion was an age of less than 16 years. The study was approved by the local review board, namely the 'Kantonale Ethikkomission Zurich' (KEK-ZH-Nr. 2010-0211).
Blood pressure measurement
In each patient, repeated office BP measurements were made during visits to the outpatient clinic at the HF unit of our hospital, according to current guidelines. 11 Blood pressure was measured in supine position and on both arms using a mercury sphygmomanometer or a validated BP measuring device by a physician. All measurements were to be read to the nearest 2 mmHg. Korotkoff Phase V sounds were used as the criterion for diastolic BP (DBP). The higher of the two readings was used for analysis. Vital parameters (SBP, DBP and heart rate) were entered into the database every 6 months.
Follow-up and endpoints
The follow-up of the study patients was continuous, mostly in 3-6 month intervals in the HF outpatient clinic. Data from all patients were collected up to 30 July 2011. The median follow-up was 5.4 years. The BP changes over time as well as the occurrence of clinical events were recorded during the regular follow-up visits at our institution. The primary endpoint of this study was time to death or heart transplantation (HTx).
Statistical analysis
Categorical data are presented as counts with percentages, and continuous data as median with interquartile range (IQR).
Statistical analysis was performed using Stata Statistical Software release 13.1 (StataCorp LP, College Station, TX, USA) and R version 3. to the event (death or HTx) was analysed using Cox regression with time-dependent covariates and time-dependent strata. The Cox proportional hazards function in the survival package in R was used for these analyses. 12 There, survival is analysed as a counting process. 13 The data for a subject are presented as multiple rows or 'observations', each of which applies to an interval of observation (start, stop). Values of BP at each measurement were used for the estimation of hazard in the time interval until next measurement, censoring or event. The SBP was analysed as time-dependent covariate and time-dependent strata with chosen SBP thresholds of <90 mmHg (equal to clinical definition of hypotension), 90-109 mmHg, 110-129 mmHg and ≥130 mmHg (equal to clinical definition of hypertension). Given the variability of BP, we considered using every four instead of two subsequent measurements to describe the trend of BP over time. A regression line was constructed out of four subsequent BP values. The slope of the regression line was regarded as the rate of change of BP at the last of these four time-points and used as covariate in the following time interval. Slopes were divided into three different time-dependent strata using the first and third quartiles of these slopes as thresholds.
To address the relation of BP measurements and BP changes, we performed a multiple Cox regression analysis, with SBP and SBP change as time-dependent strata, heart rate at the corresponding measurement as time-dependent covariate, and age, gender and the co-existence of a malignant disease at initial presentation as time-independent covariates. Hazard ratios (HR) are presented with 95% confidence intervals (CI). Kaplan-Meier curves for time-dependent strata were calculated using the command 'sts' in STATA using delayed entry.
Results
Baseline characteristics
A total of 927 patients [776 male (83.7%), median age 58 years at initial presentation] were included in this study ( Table 1 ). Of these, 481 patients (51.9%) had ischaemic HF and 446 patients (48.1%) had non-ischaemic HF. Median left ventricular ejection fraction (LVEF) was 34% (IQR 25-47%), while 184 patients (19.8%) had a LVEF >50%. Most patients presented with New York Heart Association (NYHA) class II (n = 318, 34.3%) or class III (n = 280, 30.2%). Only 54 patients (5.8%) presented with NYHA class I and 23 (27.2%) patients presented with NYHA class IV; data on NYHA class were missing at initial presentation in 252 patients (27.2%).
The median SBP was 117 mmHg (IQR 104-130 mmHg), while median DBP was 76 mmHg (IQR 68-82 mmHg) ( Table 1 ). The number of examinations over time used for the analysis added up to a median of 7 (IQR 3-12).
At time of initial presentation, almost three-quarters of the patients were treated with beta-blockers or diuretics with 74.8% and 73.6%, respectively. More than half of the patients (57.7%) presented with inhibitors of the renin-angiotensin-aldosterone system at first presentation. More than one-tenth of the investigated study group was treated either with digitalis (13.8%), nitrates (12%), or calcium channel blockers (6.8%). At first consultation in the outpatient clinic of our HF unit, 172 (18.6%) patients had already been treated with an implantable cardioverter defibrillator (ICD) and 46 (5.0%) with cardiac resynchronization therapy (CRT). During our follow-up, further implantations of cardiac devices had 
Endpoints
During the follow-up period, 290 patients reached endpoints; 220 patients died, while 70 patients underwent HTx. Median survival of our patient cohort was 7.7 (95% CI 6.6-9.8) years ( Figure 1 ).
Blood pressure change
In total, 7514 time-intervals were observed. As slopes are available only after four visits of a patient, initial slopes were available in 4990 intervals. The median time-interval of four measurements of SBP to calculate a slope was 398 days. The 25th percentile of slopes was calculated as -10.07 mmHg/year; the 75th percentile was calculated +10.09 mmHg/year, giving thresholds as ±10 mmHg/year. Raw mortality was 177 in these 4990 intervals, 58 in 425 patient-years (pty) in the stratum with slope < -10 mmHg/year, 66 in 1081 pty in the stratum with most stable BP (slope between -10 and +10 mmHg/year), and 53 in 428 pty in the stratum with slope >10 mmHg per year. The stratum with the most stable BP showed the best long-term survival. The worst survival was found below the 25th percentile with a SBP reduction >10 mmHg per year (HR 2.0, 95% CI 1.4-2.9 compared with stable patients), while a SBP increase above the 75th percentile of >10 mmHg/year was found in-between (HR 1. Cox regression showed a significant difference between time-dependent strata (P < 0.001). Slope = -10 to 10 (blue): Reference (= stable patients); slope = > 10 (green): hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.2-2.6 compared with stable patients; Slope = <-10 (red): HR 2.0, 95% CI 1.4-2.9 compared with stable patients.
are statistically significant with a P-value of <0.001 and are shown in Figure 2 .
Systolic blood pressure and survival
Initial SBP measurements were available at 7453 of 7514 time-intervals. During long-term follow-up, raw mortality was 252 (48 in 102 pty in the stratum with SBP <90 mmHg, 101 in 810 pty in SBP 90-109 mmHg, 75 in 1162 pty in SBP 110-129 mmHg, and 28 in 774 pty in SBP ≥130 mmHg). Patients with the highest SBP levels (≥130 mmHg) had the best prognosis. Patients with the lowest quartile of SBP levels (<90 mmHg) had the highest mortality (HR 12.1, 95% CI 7.6-19.3 compared with SBP ≥130 mmHg), while survival of patients with SBP from 90 to 129 mmHg was in-between (overall P < 0.001) (Figure 3) . When SBP was analysed as continuous variable, a lower level of SBP (by 10 mmHg over 1 year) was associated with an increased hazard of 64% (HR 1.64, 95% CI 1.50-1.79). To estimate the confounding effects, we performed a multiple Cox regression analysis, including age, gender, and the co-existence of a malignant disease at initial presentation. Older age (≥70 years) was associated with higher mortality (HR 1.5, 95% CI 1.1-2.2) (Figure 4) . We could not find any statistical significance for male sex (HR 1.2, 95% CI 0.82-1.9) or for co-existence of malignant diseases (HR 1.0, 95% CI 0.58-1.8). The most important risk factor for increased mortality during long-term follow-up is a SBP <90 mmHg with a HR of 17 (95% CI 9.7-29) compared with the stratum with a SBP ≥130 mmHg (Figure 4 ).
Discussion
The aim of the present study was to delineate the effects of BP changes on long-term survival in patients with CHF outside a randomized controlled trial. We found that significant changes in SBP (±10 mmHg/year) are associated with increased mortality. In particular, a SBP change of < -10 mmHg over 1 year led to an increased hazard of 64% (HR 1.64, 95% CI 1.50-1.79) (Figure 2) . 
Figure 4
Result of multiple Cox regression displayed as forest plot. Adjusted for heart rate as time-dependent covariate as well as age, gender and the coexistence of a malignant disease at initial presentation as time-independent covariates. CI, confidence interval; HR, hazard ratio; SBP, systolic blood pressure.
We are aware that measurements of BP cannot substitute other, more accurate and detailed markers for cardiac output in CHF populations. Indeed, BP is simple to measure and available almost everywhere, and therefore of paramount clinical importance in guiding therapy of patients with HF. Arterial hypertension is regarded as one of the most frequent co-morbidities 14 and precursors of HF. 2 The concept of 'reverse epidemiology' suggests that in contrast to hypertensive patients, patients with CHF and elevated BP levels have an improved survival. 15 While this concept is in line with some studies, other investigations led to different conclusions. Hence, data from the prospective Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, which included 15 245 hypertensive patients, suggest no evidence for an increase in adverse outcome in patients with low BP, 16 data from the Framingham study showed a J-shaped relationship between DBP and myocardial infarction and HF, in patients with and without antihypertensive therapy.
17 Furthermore, in a cohort of patients suffering from coronary artery disease a similar relationship was described by Bangalore et al., 18 showing a J-curve with increased HRs at low and high SBP. Sim and colleagues 19 also presented related results in a population of hypertensive patients, demonstrating worsened outcomes among those with lower treated SBP compared with a reference group with SBP ranges of 130-139 mmHg. More recent data from the prospective Systolic Blood Pressure Intervention Trial (SPRINT) showed an improvement in outcomes (myocardial infarction, other acute coronary syndrome, stroke, HF or cardiovascular death) in intensively treated patients with a mean BP after treatment of 121.4 mmHg, compared with a less intensively treated group. 20 In that study, however, patients with HF were excluded.
While the association between low BP and prognosis in the general population remains controversial, retrospective analyses from clinical trials suggest an inverse relationship between BP and prognosis. 21 Lee and colleagues 21 retrospectively analysed data from the Digitalis Investigation Group (DIG) trial. 22, 23 This cohort included 6800 patients with a mean LVEF of 28 ± 9% and a median follow-up of 38 months (range 28-58 months). 21 The authors found a significantly increased mortality in patients with a SBP <100 mmHg compared with patients with a SBP of 130-139 mmHg (HR 1.80, 95% CI 1.36-2.38, P < 0.001). 21 However, medical therapy in HF is of paramount importance, as it contributes to BP in these patients. In this analysis of the DIG trial, it remained unclear how many patients were on target doses of their HF medication and the use of beta-blockers or aldosterone antagonists was not tracked during the trial. 21 Therefore, increased mortality in patients with low BP may be attributed to a limited number of patients that reached target doses or to their intrinsic low BP, illness severity or other factors. 21 These data are in line with our findings that a low BP (<90 mmHg) compared with a higher BP (≥130 mmHg) is associated with 17-fold increased mortality in outpatients with CHF. Similar findings were reported by Raphael et al., 24 showing the relationship of BP and mortality in CHF in a meta-analysis of 10 different studies. The results confirm that a higher SBP was a favourable prognostic marker in CHF, with a 13% lower mortality associated with a 10 mmHg higher SBP.
Hence, the relationship between cardiovascular events and BP appears to be multifactorial, and variables other than absolute BP levels alone may play an important role in the pathophysiology of patients with CHF. 25 The variability of BP across outpatient visits is usually dismissed as random fluctuation around a 'true' or 'usual' BP. 9 In recent years, other factors, such as BP variability, emerged as having prognostic importance. 25 Traditionally, BP variability was assessed over 24 h using ambulatory BP measurement. 26 A decreased short-term BP variability is regarded as an index of sympathetic vascular modulation and is associated with increased mortality in CHF patients. 27, 28 Data from high-risk cardiovascular patients suggest that high visit-to-visit BP variability over longer follow-up periods may have greater prognostic value than average BP measurements or short-term BP variability alone. 10, 25, 26, 29 However, data in CHF patients are sparse. The Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan (HEAAL) study demonstrated that a high dose of losartan (150 mg) is superior in reducing morbidity and mortality in patients with symptomatic HF compared with a lower dose (50 mg). 30 A retrospective analysis of this randomized controlled trial showed an association of poor clinical outcomes and increased visit-to-visit BP variability. 10 Data from the present study expand this knowledge to daily clinical practice as we demonstrate reduced mortality in CHF patients with long-term stability of BP. In the present study, a long-term BP change >10 mmHg within 1 year of regular clinical follow-up was associated with increased mortality, while patients with a stable BP tended to have the best survival. These findings may be explained by the development of an autonomous BP variability phenotype which may be paralleled by the progressive and sustained organ damage in severe HF. 10 Interestingly, data from the HEAAL trial and the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) found increased variability in BP in patients treated with beta-blockers, although this treatment is associated with improved outcomes, 10,31 while treatment with the angiotensin-receptor blocker losartan or the calcium channel blocker amlodipine was not associated with higher variability in BP. Our patient cohort represents the typical heart population of a tertiary medical centre. Although we cannot completely exclude the influence of potential confounders, only age >70 years was identified as a marker of worse prognosis. It is well known that 50% of the patients with CHF die within 4 years and those with severe CHF have even worse survival -less than half will survive the first year after their diagnosis. 32 However, in our patient cohort the median survival is 7.7 years, which is a significantly better result compared with international data.
Limitations
Our study has two main limitations: first, the statistical analysis was performed retrospectively, and second, data presented in this analysis represent the patient population of a tertiary medical centre. Whether these findings apply to other patient populations remains still elusive.
Conclusion
Increased long-term changes in BP were found to be associated with worse prognosis in patients with CHF in the real-world setting of a tertiary university HF centre. Not only the patients with a low SBP (<90 mmHg), but also those with high visit-to-visit BP changes showed a significantly worse prognosis. Variable BP levels were associated with a decisively higher mortality in comparison with those with stable values, regardless of whether BP increased or decreased (> + 10 mmHg or < -10 mmHg) over 1 year. Furthermore, low SBP (<90 mmHg) implied significantly elevated all-cause mortality in comparison with the strata with higher maintained SBP values. These data suggest that further treatment strategies in patients with CHF should also focus on the role of long-time BP variability. Whether a stabilization of long-term BP will improve cardiovascular morbidity and mortality should be addressed in large prospective outcome trials.
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